Differences

This shows you the differences between two versions of the page.

--- home:diseases:eyes [01.26.2019] – [Recent research into AMD] sallieq
+++ home:diseases:eyes [02.11.2019] – [Initial response to olmesartan] sallieq
@@ Line 19: / Line 19: @@
 ===== Marshall Protocol for chronic eye diseases =====
 ==== Initial response to olmesartan ====
-It should be noted that some patients experience a drop in eye inflammation as soon as they start the ARB medication olmesartan.  This is because aside from its ability to stimulate the innate immune system, olmesartan has significant anti-inflammatory properties. Benicar binds and blocks the Angiotensin Receptor, decreasing levels of Nuclear Factor Kappa B, a protein that stimulates the release of inflammatory cytokines - causing a drop in inflammation.  For example, when researchers at the Keio University School of Medicine used a bacterial endotoxin to create a condition similar to uveitis in mice, they found that the eye inflammation of the animals decreased significantly after they were administered the ARB Telmisartan.(({{pubmed>long:16043867}}))
+It should be noted that some patients experience a drop in eye inflammation as soon as they start the ARB medication olmesartan.  This is because aside from its ability to stimulate the innate immune system, olmesartan has significant anti-inflammatory properties. Benicar binds and blocks the Angiotensin Receptor, decreasing levels of Nuclear Factor Kappa B, a protein that stimulates the release of inflammatory cytokines - causing a drop in inflammation.
+When researchers at the Keio University School of Medicine used a bacterial endotoxin to create a condition similar to uveitis in mice, they found that the eye inflammation of the animals decreased significantly after they were administered [[home:othertreatments:immune_suppressants:telmisartan|Telmisartan]],
+ (a dangerously different ARB).(({{pubmed>long:16043867}}))

home/diseases/eyes.txt · Last modified: 09.14.2022 by 127.0.0.1